 "Claris Lifesciences gains on ANDA approval for Bupivacaine injection")
Claris Lifesciences rallied nearly 8% to Rs 270 on the BSE after the company announced that it has received Abbreviated New Drug Application (ANDA) approval for Bupivacaine injection. The stock is trading at its 52-week high after rebounding 10% from its intra-day low of Rs 246.
“The company has received Abbreviated New Drug Application (ANDA) approval for Bupivacaine Hydrochloride in 8.25% Dextrose injection USP, 7.5 mg/ml, single-dose ampules with 2 ml fill volumes, in the United States of America (US),” Claris Lifesciences said in release.
Bupivacaine Hydrochloride is Dextrose injection is a local or regional anesthesia used as a long-acting anesthetic during surgical procedures.
With this approval Claris now has a total of 15 approvals and 25 under approval ANDAs, the total addressable market size of the approved ANDAs is estimated to be little above US$ 300 million, it added.
At 12:44 PM, the stock was up 5% at Rs 263 on the BSE. Around 370,000 shares changed hands so far against an average sub 75,000 shares that were traded daily in past two weeks on the BSE.
“The company has received Abbreviated New Drug Application (ANDA) approval for Bupivacaine Hydrochloride in 8.25% Dextrose injection USP, 7.5 mg/ml, single-dose ampules with 2 ml fill volumes, in the United States of America (US),” Claris Lifesciences said in release.
Bupivacaine Hydrochloride is Dextrose injection is a local or regional anesthesia used as a long-acting anesthetic during surgical procedures.
With this approval Claris now has a total of 15 approvals and 25 under approval ANDAs, the total addressable market size of the approved ANDAs is estimated to be little above US$ 300 million, it added.
At 12:44 PM, the stock was up 5% at Rs 263 on the BSE. Around 370,000 shares changed hands so far against an average sub 75,000 shares that were traded daily in past two weeks on the BSE.